anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a blood circulation smoothing bean, which is a specific nutritional food bean. Being developed according to modern theories combining traditional Chinese and western medicine, the blood circulation smoothing bean has the efficacy of replenishing qi and blood, resisting thrombus, resisting coagulation, reducing blood fat, lowering cholesterol, softening blood vessels, as well as improving microcirculation, and is suitable to be taken by people at the rehabilitation period of cardiovascular-cerebrovascular diseases and the sub-health group. In order to solve the technical problems of the blood circulation smoothing bean, the invention employs the following technical scheme that: according to the causes and pathogenesis of human body qi-blood circulation and cardiovascular-cerebrovascular diseases, the blood circulation smoothing bean theoretically adopts a formula involving traditional Chinese medicines  with the efficacy of replenishing qi and blood, resisting thrombus, resisting coagulation, reducing blood fat, lowering cholesterol, softening blood vessels, as well as improving microcirculation, and white granulated sugar. Specifically, the formula involves white granulated sugar and the following 9 traditional Chinese medicines: soybeans, Dioscorea alata L., Caulis Spatholobi, lumbricus, radix achyranthis bidentatae, Radix Aucklandiae, Mucuna sempervirens Hemsl, safflower, and ground beeltles. During production, the soybeans are stir-fried well, the traditional Chinese medicines and the white granulated sugar are crushed and subjected to coating, and a bagged edible nutritional bean can be prepared by a modern food production technology. The blood circulation smoothing bean provided in the invention preserves the customs of Chinese traditional food culture, reflects traditional Chinese and western medicine combined theories integrating the blood circulation smoothing bean name with the causes and pathogenesis of human body qi-blood circulation and cardiovascular-cerebrovascular diseases and the clinical efficacy, and reflects the new technological characteristics of food preparation by modern machinery.
Chronic smokers have increased risk of fibrosis-related atrial fibrillation. The use of heated-tobacco products (HTPs) is increasing exponentially, and their health impact is still uncertain. We aim to investigate the effects of circulating molecules in exclusive HTP chronic smokers on the fibrotic behavior of human atrial cardiac stromal cells (CSCs). CSCs were isolated from atrial tissue of elective cardiac surgery patients, and exposed to serum lots from young healthy subjects, stratified in exclusive HTP smokers, tobacco combustion cigarette (TCC) smokers, or nonsmokers (NS). CSCs treated with TCC serum displayed impaired migration and increased expression of pro-inflammatory cytokines. Cells cultured with HTP serum showed increased levels of pro-fibrotic markers, and reduced expression of connexin-43. Both TCC and HTP sera increased collagen release and reduced secretion of angiogenic protective factors from CSCs, compared to NS serum. Paracrine support to tube-formation by endothelial cells and to viability of cardiomyocytes was significantly impaired. Treatment with sera of both smokers groups impaired H2O2/NO release balance by CSCs and reduced early phosphorylation of several pathways compared to NS serum, leading to mTOR activation. Cotreatment with rapamycin was able to reduce mTOR phosphorylation and differentiation into aSMA-positive myofibroblasts in CSCs exposed to TCC and HTP sera. In conclusion, the circulating molecules in the serum of chronic exclusive HTP smokers induce fibrotic behavior in CSCs through activation of the mTOR pathway, and reduce their beneficial paracrine effects on endothelial cells and cardiomyocytes. These results point to a potential risk for cardiac fibrosis in chronic HTP users.
PURPOSE:A pack, containing titanium dioxide or silicon dioxide lipophilized by the silicon coating, and having remarkably improved removing effect on lipophilic stainsor sebums. CONSTITUTION:A pack containing 0.2-30.0wt% titanium dioxide or silicon dioxide lipophilized by the silicon coating. The incorporation of the lipophilic inorganic substance permits the very effective removal of lipophilic stains or sebums. The lipophilization of the titanium dioxide or silicon dioxide is carried out by mixing the compound 99 deg. ethanol with silicon in a mixer with stirring thoroughly, and baking the resultant uniform mixture, e.g. at 150 deg.C for 3hr in the case of coating concentration of 1%.
DTX301 (scAAV8OTC) 2.0 × 10\^12 GC/kg will be administered as a single peripheral IV infusion. A reactive corticosteroid taper regimen will be administered to control transient vector-induced hepatic effects. Sodium acetate will be used as a tracer to measure the rate of ureagenesis.
BACKGROUND: The prevalence of depression among people with chronic pain remains unclear due to the heterogeneity of study samples and definitions of depression. We aimed to identify sources of variation in the prevalence of depression among people with chronic pain and generate clinical prediction models to estimate the probability of depression among individuals with chronic pain.
METHODS: Participants were from the UK Biobank. The primary outcome was a "lifetime" history of depression. The model's performance was evaluated using discrimination (optimism-corrected C statistic) and calibration (calibration plot).
RESULTS: Analyses included 24,405 patients with chronic pain (mean age 64.1 years). Among participants with chronic widespread pain, the prevalence of having a "lifetime" history of depression was 45.7% and varied (25.0-66.7%) depending on patient characteristics. The final clinical prediction model (optimism-corrected C statistic: 0.66; good calibration on the calibration plot) included age, BMI, smoking status, physical activity, socioeconomic status, gender, history of asthma, history of heart failure, and history of peripheral artery disease. Among participants with chronic regional pain, the prevalence of having a "lifetime" history of depression was 30.2% and varied (21.4-70.6%) depending on patient characteristics. The final clinical prediction model (optimism-corrected C statistic: 0.65; good calibration on the calibration plot) included age, gender, nature of pain, smoking status, regular opioid use, history of asthma, pain location that bothers you most, and BMI.
CONCLUSIONS: There was substantial variability in the prevalence of depression among patients with chronic pain. Clinically relevant factors were selected to develop prediction models. Clinicians can use these models to assess patients' treatment needs. These predictors are convenient to collect during daily practice, making it easy for busy clinicians to use them.
FIELD: medicine. SUBSTANCE: invention relates to the development of complex homeopathic agents for treatment of patients with cystic fibrosis mastopathy. The proposed agent has Hydrastis canadensis C6, Kalium jodatum C3, Thuja occidentalis C3, Conium maculatum C3, Phytolacca americana C3, Marsdenia condurango C3 being all components are taken at equal parts. An agent can be made as sugar granules. Treatment with the proposed agent results to the improvement of the general state, disappearance or decrease of headache, foot and hand edemas, discomfort state before menstruation onset and anxiety and imbalance change for the comfort state, pain condensations and cystic forms in breast are decreased or softened, blood plasma progesterone and prolactin levels are normalized to physiological values. EFFECT: enhanced effectiveness of the drug. 2 cl, 1 ex
Left ventricular non-compaction (LVNC) is a myocardial disease characterized by a two-layered structure typically seen at the apical and lateral left portions of the ventricular myocardium, distal to the papillary muscles. While considered a rare disease, its prevalence in children is increasing due to the increased awareness of this condition and improved resolution of imaging techniques. The etiology is heterogeneous, ranging from inherited conditions to acquired diseases. Although many patients are asymptomatic, some patients may experience adverse events, including heart failure, arrhythmias, or thromboembolic events. Several echocardiographic or cardiac magnetic resonance imaging diagnostic criteria have been proposed for diagnosing LVNC. However, their application in children is significantly limited. This review aims to describe the clinical and genetic characteristics of children with LVNC and discuss the role of the proposed diagnostic criteria.
Kids between 10 and 16. ADHD, Asperger or ODD, with lack of aggressiveness control.
PCT No. PCT/US92/06809 Sec. 371 Date Feb. 9, 1994 Sec. 102(e) Date Feb. 9, 1994 PCT Filed Aug. 13, 1992.The release of bradykinin into the circulatory system is potentiated by administration of a polypeptide having an amino acid sequence corresponding to domain 3 of the human kininogen heavy chain. The polypeptide competitively inhibits the binding of high and low molecular weight kininogen to platelets and other cells which protect the kininogens from kallikrein cleavage, thereby increasing the level of bradykinin in the cirulation. The resulting in vivo effect is an intravascular elevation of bradykinin and concomitant lowering of blood pressure. The domain 3 polypeptide also inhibits thrombin-induced platelet and endothelial cell activation.
Skeletal muscle weakness is a debilitating consequence of many malignancies. Muscle weakness has a negative impact on both patient wellbeing and outcome in a range of cancer types and can be the result of loss of muscle mass (i.e. muscle atrophy, cachexia) and occur independently of muscle atrophy or cachexia. There are multiple cancer specific triggers that can initiate the progression of muscle weakness, including the malignancy itself and the tumour environment, as well as chemotherapy, radiotherapy and malnutrition. This can induce weakness via different routes: 1) impaired intrinsic capacity (i.e., contractile dysfunction and intramuscular impairments in excitation-contraction coupling or crossbridge cycling), 2) neuromuscular disconnection and/or 3) muscle atrophy. The mechanisms that underlie these pathways are a complex interplay of inflammation, autophagy, disrupted protein synthesis/degradation, and mitochondrial dysfunction. The current lack of therapies to treat cancer-associated muscle weakness highlight the critical need for novel interventions (both pharmacological and non-pharmacological) and mechanistic insight. Moreover, most research in the field has placed emphasis on directly improving muscle mass to improve muscle strength. However, accumulating evidence suggests that loss of muscle function precedes atrophy. This review primarily focuses on cancer-associated muscle weakness, independent of cachexia, and provides a solid background on the underlying mechanisms, methodology, current interventions, gaps in knowledge, and limitations of research in the field. Moreover, we have performed a mini-systematic review of recent research into the mechanisms behind muscle weakness in specific cancer types, along with the main pathways implicated.
A method for the delivery of therapeutic agents across the blood brain barrier is disclosed which utilizes drug neutralization technology, and the selective permeability of the blood brain barrier (BBB). During and after the formation of brain lesions, the BBB becomes increasingly permeable. To treat these conditions, a therapeutically effective amount of a selected drug is administered having a molecular weight and other characteristics allowing passage of the drug through the modified BBB. Thereafter, a neutralizing material specific to the drug is administered. The neutralizing material has a high molecular weight and/or some other characteristic(s) which prevent its passage through the modified BBB. The neutralizing material binds to or reacts with the excess drug circulating outside the BBB, in order to prevent the manifestation of drug toxicity problems.
OBJECTIVE: Upper urinary tract stones (UUTSs) are among the most common types of urinary stones, and their incidence rate has been increasing annually in recent years, seriously affecting the daily lives of patients. This study aimed to compare the treatment efficacy of one-stage and staged flexible ureteroscopic lithotripsy (FURL) for UUTSs.
METHODS: A total of 142 patients with UUTSs admitted to our hospital between December 2019 and March 2023 were selected for retrospective analysis, including 76 patients who received staged FURL (control group) and 66 patients who received one-stage FURL (observation group). The duration of surgery, length of stay, stone clearance rate, incidence of postoperative complications (from postsurgery to discharge), and total hospitalization cost were analyzed in both groups. The visual analog scale (VAS) score and activities of daily living (ADL) score were assessed before surgery (T0), 3 days after surgery (T1), and 7 days after surgery (T2). Patients were followed up for 1 month after surgery, and their quality of life was assessed using the MOS Item Short Form Health Survey (SF-36).
RESULTS: There was no difference in the stone clearance rate or incidence of postoperative complications between the two groups (p > 0.05). The operation time, hospitalization time and hospitalization cost in the observation group were 75.58 ± 15.91 min, 4.20 ± 1.24 days and 14312.62 ± 1078.89 yuan, respectively, which were lower than those in the control group (p < 0.05). In addition, the VAS score at T3 was decreased to 1.49 ± 0.70, while the ADL and SF-36 scores were higher in the observation group (p < 0.05).
CONCLUSIONS: One-stage FURL shortens the duration of surgery and length of stay, reduces hospitalization costs, and improves the quality of life of patients with UUTSs.
Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 8 am. to 4 pm.), maintaining 16 fasting hours (from 4 pm. to 8 am. the following day).
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that severely impacts affected persons' speech and motor functions, yet early detection and tracking of disease progression remain challenging. The current gold standard for monitoring ALS progression, the ALS functional rating scale - revised (ALSFRS-R), is based on subjective ratings of symptom severity, and may not capture subtle but clinically meaningful changes due to a lack of granularity. Multimodal speech measures which can be automatically collected from patients in a remote fashion allow us to bridge this gap because they are continuous-valued and therefore, potentially more granular at capturing disease progression. Here we investigate the responsiveness and sensitivity of multimodal speech measures in persons with ALS (pALS) collected via a remote patient monitoring platform in an effort to quantify how long it takes to detect a clinically-meaningful change associated with disease progression. We recorded audio and video from 278 participants and automatically extracted multimodal speech biomarkers (acoustic, orofacial, linguistic) from the data. We find that the timing alignment of pALS speech relative to a canonical elicitation of the same prompt and the number of words used to describe a picture are the most responsive measures at detecting such change in both pALS with bulbar (n = 36) and non-bulbar onset (n = 107). Interestingly, the responsiveness of these measures is stable even at small sample sizes. We further found that certain speech measures are sensitive enough to track bulbar decline even when there is no patient-reported clinical change, i.e. the ALSFRS-R speech score remains unchanged at 3 out of a total possible score of 4. The findings of this study have the potential to facilitate improved, accelerated and cost-effective clinical trials and care.
The invention relates to a pH and oxidation-reduction dual-sensitive layer cross-linking nanoparticle as well as a preparation method and an application thereof. A hydrophilic layer which at least contains PCB (Polycarboxylate Betaine) or PEG (Polyethylene Glycol) is positioned on the surface of the nanoparticle, a hydrophobic nuclei which at least contains a pH-sensitive polymer unit is positioned in the nanoparticle, and an S-S (Disulfide Bond) cross-linking layer which is formed through cross-linking reaction between PDS (Polymethacrylamide Ehtylpyridine Disulfide) units is positioned between the hydrophilic layer and the hydrophobic nuclei. A tumor targeted group can be modified on the hydrophilic layer positioned on the surface of the pH and oxidation-reduction dual-sensitive layer cross-linking nanoparticle, and the gathering of the nanoparticle on a tumor tissue and the endocytosis of the nanoparticle on the tumor cell are accelerated through the specific targeted effect of the nanoparticle on a tumor cell. The pH and oxidation-reduction dual-sensitive layer cross-linking nanoparticle disclosed by the invention has the advantages of good biocompatibility and low toxicity. According to the pH and oxidation-reduction dual-sensitive layer cross-linking nanoparticle, a cross-linked structure is dissociated under the action of glutathione inside the tumor cell, so that the release of a medicine is promoted. The preparation method disclosed by the invention is simple, convenient, good in stability and conveniently operated and popularized.
Adult patients (18-65 years old) with body mass index \> 30 kg/mˆ2 treated with a single oral dose of 40 mg simvastatin for Pk analysis. Blood samples collected for blood tests, genomics and transcriptomic analysis.
Piperacillin and tazobactam for injection, USP is an injectable antibacterial combination product consisting of the semisynthetic antibacterial piperacillin sodium and the beta-lactamase inhibitor tazobactam sodium for intravenous administration.

Piperacillin sodium is derived from D(-)-α-aminobenzyl-penicillin. The chemical name of piperacillin sodium is sodium (2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazine-carboxamido)-2- phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate. The chemical formula is C23H26N5NaO7S and the molecular weight is 539.5. The chemical structure of piperacillin sodium is:

Tazobactam sodium, a derivative of the penicillin nucleus, is a penicillanic acid sulfone. Its chemical name is sodium (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide. The chemical formula is C10H11N4NaO5S and the molecular weight is 322.3. The chemical structure of tazobactam sodium is:

Piperacillin and tazobactam for injection, USP contains a total of 2.35 mEq (54 mg) of sodium (Na+) per gram of piperacillin in the combination product.

Piperacillin and tazobactam for injection, USP is a white to off-white sterile, cryodesiccated powder consisting of piperacillin and tazobactam as their sodium salts packaged in glass vials. The product does not contain excipients or preservatives.

  * Each piperacillin and tazobactam for injection, USP 2.25 g single-dose vial contains an amount of drug sufficient for withdrawal of piperacillin sodium equivalent to 2 grams of piperacillin and tazobactam sodium equivalent to 0.25 g of tazobactam. Each vial contains 4.69 mEq (108 mg) of sodium.
  * Each piperacillin and tazobactam for injection, USP 3.375 g single-dose vial contains an amount of drug sufficient for withdrawal of piperacillin sodium equivalent to 3 grams of piperacillin and tazobactam sodium equivalent to 0.375 g of tazobactam. Each vial contains 7.04 mEq (162 mg) of sodium.
  * Each piperacillin and tazobactam for injection, USP 4.5 g single-dose vial contains an amount of drug sufficient for withdrawal of piperacillin sodium equivalent to 4 grams of piperacillin and tazobactam sodium equivalent to 0.5 g of tazobactam. Each vial contains 9.39 mEq (216 mg) of sodium.
A stable, substantially anhydrous (not more than 1, and preferably 0.5, per cent water), homogeneous liquid polyvitamin preparation comprises both water-soluble and fat-soluble vitamins in a vehicle consisting essentially of propylene glycol and a water-soluble polyoxy-alkylene oxide derivative of a fatty acid (not less than 12 C atoms) partial ester of a hexitan, said vehicle constituting the major proportion, preferably at least 80 per cent by weight, of the preparation, the propylene glycol being 0.5 to 2 parts by weight per part of the hexitan derivative. Polyoxyalkylene derivatives of sorbitan with acids such as lauric, stearic, palmitic and oleic, where the alkylene oxide is ethylene oxide or propylene oxide, present as 16 to 25 oxide groupings, e.g. "Tweens" (Registered Trade Mark), are preferred.  The "Tween" is preferably dried in vacuo.  One or more fat soluble vitamins are dissolved in the "Tween," the water-soluble vitamins are dissolved in the propylene glycol, and the solutions so formed are mixed, the operations being carried out in the presence of an inert gas e.g. nitrogen or CO2.  If the propylene glycol has not been previously dried, the vitamin preparation is dried over an agent insoluble in propylene glycol e.g. anhydrous sodium sulphate, anhydrous calcium sulphate or activated alumina.  In one example, vitamin A, vitamin D2, oil of limes and d-pantothenyl alcohol are dissolved in polyoxyethylene sorbitan mono-oleate at 50 DEG  C. under CO2. To this is added a solution of urea, nicotinamide, riboflavin, ascorbic acid, pyridoxine hydrochloride, thiamin HCl and saccharin at 50 DEG  C.  Other specified vitamins are vitamin A palmitate, vitamin A acetate, thiamine mono-nitrate and a -tocopherol acetate.  The multi-vitamin preparation may be mixed with orange juice, milk, cereals, strained or chopped meats, vegetables, fruits, puddings, soups and other foods.  Specification 588,298 is referred to.
Drug-induced liver injury (DILI) is an adverse reaction to medications and other xenobiotics that leads to liver dysfunction. Based on differential clinical patterns of injury, DILI is classified into hepatocellular, cholestatic, and mixed types; although hepatocellular DILI is associated with inflammation, necrosis, and apoptosis, cholestatic DILI is associated with bile plugs and bile duct paucity. Ursodeoxycholic acid (UDCA) has been empirically used as a supportive drug mainly in cholestatic DILI, but both curative and prophylactic beneficial effects have been observed for hepatocellular DILI as well, according to preliminary clinical studies. This could reflect the fact that UDCA has a plethora of beneficial effects potentially useful to treat the wide range of injuries with different etiologies and pathomechanisms occurring in both types of DILI, including anticholestatic, antioxidant, anti-inflammatory, antiapoptotic, antinecrotic, mitoprotective, endoplasmic reticulum stress alleviating, and immunomodulatory properties. In this review, a revision of the literature has been performed to evaluate the efficacy of UDCA across the whole DILI spectrum, and these findings were associated with the multiple mechanisms of UDCA hepatoprotection. This should help better rationalize and systematize the use of this versatile and safe hepatoprotector in each type of DILI scenarios.
Subjects will receive belantamab mafodotin at escalating doses of 2.5 milligrams per kilograms (mg/kg) and 3.4 mg/kg along with 200 mg pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day cycle to establish RP2D. There will be maximum of 35 cycles of combination treatment.